Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director Sells 1,250 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock in a transaction on Friday, September 15th. The stock was sold at an average price of $45.34, for a total transaction of $56,675.00. Following the sale, the director now directly owns 367,420 shares of the company’s stock, valued at $16,658,822.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Alec Machiels also recently made the following trade(s):

• On Monday, July 17th, Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $64.79, for a total transaction of $80,987.50.
• On Tuesday, June 20th, Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $88.41, for a total value of $110,512.50.

Apellis Pharmaceuticals Stock Up 5.8 %

APLS stock traded up $2.56 on Monday, hitting $47.00. The company had a trading volume of 2,633,882 shares, compared to its average volume of 2,764,695. The company has a current ratio of 5.11, a quick ratio of 4.52 and a debt-to-equity ratio of 0.27. The stock’s 50-day simple moving average is $40.45 and its 200 day simple moving average is $66.75. Apellis Pharmaceuticals, Inc. has a 12-month low of $19.83 and a 12-month high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Monday, July 31st. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.33. Apellis Pharmaceuticals had a negative return on equity of 212.82% and a negative net margin of 356.02%. The firm had revenue of $95.00 million for the quarter, compared to the consensus estimate of $70.38 million. During the same period last year, the business posted ($1.46) EPS. The company’s revenue for the quarter was up 482.8% on a year-over-year basis. On average, research analysts expect that Apellis Pharmaceuticals, Inc. will post -4.89 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on APLS shares. UBS Group increased their target price on shares of Apellis Pharmaceuticals from $60.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, August 23rd. JPMorgan Chase & Co. cut Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $72.00 to $60.00 in a research note on Thursday, August 3rd. Bank of America raised their price target on Apellis Pharmaceuticals from $40.00 to $43.00 and gave the stock a “neutral” rating in a research note on Friday, September 8th. Raymond James reduced their price objective on shares of Apellis Pharmaceuticals from $156.00 to $89.00 and set a “strong-buy” rating on the stock in a research report on Tuesday, August 1st. Finally, Wells Fargo & Company raised Apellis Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $34.00 to $64.00 in a research note on Friday. Five research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $66.13.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently made changes to their positions in the business. Clearstead Advisors LLC purchased a new stake in Apellis Pharmaceuticals in the 1st quarter worth $27,000. National Bank of Canada FI purchased a new stake in shares of Apellis Pharmaceuticals during the 2nd quarter valued at about $33,000. IFP Advisors Inc raised its position in Apellis Pharmaceuticals by 49,525.0% during the first quarter. IFP Advisors Inc now owns 1,985 shares of the company’s stock valued at $39,000 after purchasing an additional 1,981 shares during the period. Focused Wealth Management Inc purchased a new stake in Apellis Pharmaceuticals during the 2nd quarter valued at $45,000. Finally, US Bancorp DE boosted its stake in shares of Apellis Pharmaceuticals by 391.2% during the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after purchasing an additional 884 shares during the period. Institutional investors own 90.43% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).